Day 2: Wednesday, September 17Wednesday, 17 September 2025

• Progressing a novel AI-driven platform to develop small molecule antagonists of CB1Rs to reduce food seeking behaviours

• Accelerating development timelines, from concept to IND approval in 19 months

• Biology and genetics of MC4R-deficiency
• Discovery and pharmacology of small molecules stabilizers of misfolded MC4R

• Highlighting a novel approach to treat obesity via inflammation reduction

• Designing a NLP3 inflammasome inhibitor to combat inflammatory response by blocking release of proinflammatory cytokines IL-1B and IL-18

• Discussing Phase 2 clinical updates

Exploring an innovative beaded oral glucose formulation which reactivates the body's natural nutrient-sensing enteroendocrine cells in the gastrointestinal tract to restore the release of multiple endogenous hormones including GLP-1 and PYY for improved glucose tolerance and weight management

Utilizing siRNA to silence two crucial obesity-associated genes, liver-specific INHBE and adipose-specific ACVR1C to improve fat distribution and metabolic control in patients respectively, as a durable and long-lasting treatment option.

• RES-101, a first-in-class miR-22 inhibitor, restores lipid biosynthesis and drives adipose browning for sustained reduction of unhealthy fat and improved body composition.

• RES-010 as a disease-modifying backbone that can be synergistically combined with other therapeutic modalities.

• Exploring two first-in-class siRNA therapeutics, ARO-INHBE and ARO-ALK7, targeting INBHE and ALK7 genes, for body weight reduction with improved preservation of lean muscle mass.

• Sharing Phase 1 clinical updates

Highlighting a once-weekly injectable notch-inhibiting novel poly nanoparticle therapeutic, ADPO-002NP, to increase mitochondrial biogenesis in white adipose tissue and initiate browning for increased calorie expenditure

• Designing a first-in-class small molecules to simultaneously inhibit ferroptosis pathways and regulate mitochondrial function, creating a synergistic approach that addresses both energy metabolism and oxidative stress, offering promising applications for obesity and beyond

• Developing an oral small molecule controlled metabolic accelerator (CMA) for ANT channel activation to induce mitochondrial uncoupling.

• Achieving selective reduction of fat tissue whilst sparing skeletal muscle mass

• Reviewing the impact of the obesity therapeutics on consumer behaviour

• Discussing future changes to the food industry as anti-obesity drugs progress, from ingredient sourcing to retail dynamics

• Discussing the influence of the obesity therapeutics on full patient health

• How is GLP-1R modulation being harnessed to treat broader disease areas?

• What next steps must be taken to better predict wider beneficial outcomes of anti-obesity drugs?

• How can digital health platforms support treatment for comorbidities?